France Digital Biomarkers Market Insight
Published: 02 September 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The France Digital Biomarkers Market is expected to see considerable growth with a CAGR of 22.25% due to an increased use of wearable health devices, an increase in chronic disease prevalence, increased use of digital health tools for patient monitoring, developments in AI and data analytics, and an increased preference for personalized and preventive healthcare measures.
France Digital Biomarkers Market Insights Forecasts to 2035
- The France Digital Biomarkers Market Size Was Estimated USD 121.5 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 22.25% from 2025 to 2035
- The France Digital Biomarkers Market Size is Expected to rise around USD 906.2 Million by 2035
Notable Insights for the France Digital Biomarkers Market
- The collection system type-based market segmentation shows that Wearables have gained the upper hand in the France Digital Biomarkers Market because of their extensive use in tracking physical activities, heart rate, sleep patterns, and chronic conditions.
- The end user based segmentation shows that the involvement of Pharmaceutical Companies and Clinical Research Organizations in the France Digital Biomarkers Market is crucial since digital biomarkers are extensively used in clinical trials and drug development programs.
- AliveCor Inc. continues to grow in strength within the digital biomarkers market segment due to its artificial intelligence-powered cardiac monitor solutions and FDA-approved KardiaMobile device.
- The improvements in artificial intelligence, machine learning, remote patient monitoring, and real world data analytics are bound to boost the growth of the market due to enhanced efficiency and predictive power of digital biomarkers.
Download the eBook (ToC)
Research Methodologies Used to Analyze the France Digital Biomarkers Market
The France digital biomarkers market is analyzed by a blend of primary and secondary research approaches for ensuring accurate information about the market and its forecasted performance. Primary research is conducted through discussions with digital biomarker developers, wearable device manufacturers, healthcare organizations, pharmaceutical companies, research institutions, technology providers, and industry experts to analyze technology adoption trends, product innovations, clinical applications, and competitive developments. Secondary research involves analyzing company reports, government healthcare publications, industry journals, scientific literature, healthcare databases, market reports, and regulatory publications related to digital health and digital biomarkers. Market estimation, trend analysis, forecasting methodologies, and competitive benchmarking are utilized for estimating market size, growth opportunities, technology adoption, investment activities, and future market potential.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France Digital Biomarkers Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France Digital Biomarkers Market
- ActiGraph LLC
- AliveCor Inc.
- Koneksa
- Altoida Inc.
- Amgen Inc.
- Biogen Inc.
- Empatica Inc.
- VivoSense
- IXICO plc
- Adherium Limited
Recent Developments:
- In February 2026, AliveCor entered into a strategic alliance with Ametris for the purpose of increasing cardiac safety monitoring in clinical studies through the use of ECG monitoring systems powered by artificial intelligence.
- In January 2026, The EmbraceMini received FDA 510(k) approval from Empatica. This wearable product is meant to monitor sleep and perform sleep actigraphy and movement detection. It is an addition to the company’s digital biomarker portfolio and continuous physiology monitoring technology.
Market Segmentation:
France Digital Biomarkers Market, By Collection System Type
- Wearables
- Biosensors
- Mobile Apps
- Devices and Platforms
- Desktop Based Software
France Digital Biomarkers Market, By Type
- Wellness
- Disease
- Drugs
France Digital Biomarkers Market, By End User
- Pharmaceutical
- Life Sciences
- Medical Devices
- App Vendors
- Clinical Research Organizations
France Digital Biomarkers Market, By Technology
- Cloud Computing
- Artificial Intelligence and Machine Learning
- Augmented Reality
- Blockchain
Expert Views:
The development of the digital biomarker market in France will be facilitated by the rise in the number of chronic conditions, the growing usage of wearable health trackers, and the high demand for patient monitoring tools. The trend of artificial intelligence, machine learning, cloud computing, and personalized medicine will help boost the adoption of digital biomarkers among pharmaceutical companies, healthcare providers, and CROs. The role of wearables is expected to remain significant, whereas innovations in digital health, real-world data, and government policies may create additional growth avenues in France.
Author: Govind and Krishna By Decisions Advisors and Consulting